BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...

Acoramidis (Attruby) shows strong clinical data and rapid launch, but faces tough competition from Pfizer’s tafamidis and upcoming RNAi drugs. BBIO’s pipeline is diverse with multiple late-stage ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...

Recent discussions on X about BridgeBio Pharma (BBIO) have centered around the company's strong performance and analyst endorsements. Many users are highlighting the initiation of coverage by major ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...

BridgeBio reported net revenue of $120.7 million in the third quarter, driven primarily by $108 million in Attruby sales. However, the company missed FactSet EPS consensus by $0.06, and shares fell ...

Good afternoon. I'll be your conference operator today. [Operator Instructions] Before we begin, I'd like to remind everyone that today's call may contain forward-looking statements within the meaning ...

(Bloomberg) -- BridgeBio Pharma Inc. is challenging Pfizer Inc. and Alnylam Pharmaceuticals, Inc. with a heart medicine that it says has better results at a lower cost. But it claims rivals are using ...